1. Introduction
===============

Prion protein (PrP) is a cell-surface glycoprotein implicated in the pathogenesis of a range of neurodegenerative disorders collectively termed transmissible spongiform encephalopathies, including Creutzfeldt-Jakob disease in humans, bovine spongiform encephalopathy in cows, and chronic wasting disease in deer \[[@B1-biomolecules-04-00510],[@B2-biomolecules-04-00510],[@B3-biomolecules-04-00510],[@B4-biomolecules-04-00510]\]. Although there is no difference in the primary structure of cellular PrP (PrP^C^) and a pathogenic or scrapie form (PrP^Sc^), spectroscopic studies revealed that PrP^C^ has a high α-helical content whereas PrP^Sc^ is composed primarily of β-sheets \[[@B5-biomolecules-04-00510],[@B6-biomolecules-04-00510]\]. There are many hypotheses regarding the conversion of PrP^C^ to PrP^Sc^, but the data suggest that conversion is entirely conformational and involves no amino acid substitutions or deletions, and, thus, supports the protein-only hypothesis \[[@B2-biomolecules-04-00510]\]. Prion replication requires the conversion of PrP^C^ into PrP^Sc^, where PrP^Sc^ acts as a template and protein X functions as a chaperone \[[@B7-biomolecules-04-00510],[@B8-biomolecules-04-00510],[@B9-biomolecules-04-00510]\].

Mature human PrP (hPrP) consists of 253 amino acids ([Figure 1](#biomolecules-04-00510-f001){ref-type="fig"}). The N-terminal domain, which includes four repeats of the PHGGGWGQ octapeptide, is a flexibly disordered region. In contrast, the C-terminal domain, which includes two a-helices, two glycosylation sites, and a glycosylphosphatidylinositol (GPI) anchor, is a folded region. The middle domain includes two β-sheets and one α-helix \[[@B10-biomolecules-04-00510],[@B11-biomolecules-04-00510],[@B12-biomolecules-04-00510]\]. The hPrP region that spans amino acid residues 106--126 in the middle domain is thought to be responsible for the pathogenic properties of PrP^Sc^, including neurotoxicity, protease resistance, induction of hypertrophy, and promotion of astrocyte proliferation \[[@B13-biomolecules-04-00510],[@B14-biomolecules-04-00510],[@B15-biomolecules-04-00510],[@B16-biomolecules-04-00510],[@B17-biomolecules-04-00510]\].

![Domain structure of human prion protein (hPrP).](biomolecules-04-00510-g001){#biomolecules-04-00510-f001}

Matrix metalloproteinases (MMPs) belong to a family of Zn^2+^-binding Ca^2+^-dependent endopeptidases whose essential function is proteolysis of the extracellular matrix (ECM), a process that is required in several cellular processes \[[@B18-biomolecules-04-00510]\]. To date, 24 human MMPs that have structural similarities have been identified and categorize to soluble-type MMP (MMPs) and membrane-type MMPs (MT-MMPs). All MMPs are synthesized as latent enzymes that are either secreted or membrane-anchored. Their expression profiles and substrate specificities vary. In the early stage of MMP investigation, main study was focused on the cancer metastasis and invasion through ECM degradation. Therefore, MMP inhibitor (MMPI) was expected as candidates of attractive drug for cancer and many researcher screened MMPIs \[[@B19-biomolecules-04-00510],[@B20-biomolecules-04-00510]\]. We prepared seven kinds of recombinant MMPs, four kinds of soluble-type MMPs (MMP-2, -3, -7, -8), and three kinds of MT-MMPs (MT1-, MT3-, MT4-MMPs) to screen MMPI. However, unfortunately, there is no MMPI being applicable for clinical use because of their severe side effect such as myalgia or joint pain. Apart from ECM molecules, MMPs act on a whole array of substrates including other proteinases and MMPs, proteinase inhibitors, growth factors, cytokines, cell-surface receptors, and cell-adhesion molecules and regulate many processes, such as cell migration, proliferation, apoptosis, angiogenesis, tumor expansion, and metastasis \[[@B21-biomolecules-04-00510],[@B22-biomolecules-04-00510],[@B23-biomolecules-04-00510]\]. Six MT-MMPs have been identified so far, of which four, MT1-/MMP-14, MT2-/MMP-15, MT3-/MMP-16, and MT5-/MMP-24, have a transmembrane domain while the other two, MT4/MMP-17 and MT6-/MMP-25, have a glycosylphosphatidylinositol domain \[[@B21-biomolecules-04-00510]\]. Among MT-MMPs, MT1-MMP is thought to be a most important in cancer metastasis, because MT1-MMP activates MMP-2, which degrades ECM \[[@B24-biomolecules-04-00510]\].

In the relationship between PrP, protease K is well known to be the specific enzyme to differ PrP^C^ from a pathogenic or PrP^Sc^ derived from PrP^C^ \[[@B25-biomolecules-04-00510],[@B26-biomolecules-04-00510]\]. Recently, Altmeppen *et al.* reviewed the roles of endoproteolytic a-cleavage and shedding of PrP in neurodegeneration \[[@B27-biomolecules-04-00510]\]. Some a disintegrin and metalloproteinase domain-containing proteins (ADAMs) such as ADAM10, ADAM8, and ADAM17 are thought to contribute to a-cleavage of PrP \[[@B28-biomolecules-04-00510],[@B29-biomolecules-04-00510],[@B30-biomolecules-04-00510],[@B31-biomolecules-04-00510]\]. In addition, ADAM10 and ADAM9 are thought to contribute to shedding of PrP \[[@B32-biomolecules-04-00510],[@B33-biomolecules-04-00510],[@B34-biomolecules-04-00510]\]. Moreover, the relation ship between MMPs and pathological conditions of the central nervous system is reported \[[@B35-biomolecules-04-00510],[@B36-biomolecules-04-00510],[@B37-biomolecules-04-00510]\]. These lead us to the idea that MMPs may be one of candidate enzyme for PrP digestion.

In another aspect of PrP study, many researchers reported the metal-binding ability of PrP to a divalent metal ion such as Cu^2+^, Ni^2+^, Mn^2+^, *etc.* \[[@B38-biomolecules-04-00510]\]. Although PrP metal-binding sites have been investigated using full-length PrP^C^ or synthetic fragment peptides and it is now generally accepted that PrP^C^ binds copper *in vivo* \[[@B39-biomolecules-04-00510]\], most researchers have focused on the octarepeat region \[[@B40-biomolecules-04-00510],[@B41-biomolecules-04-00510],[@B42-biomolecules-04-00510],[@B43-biomolecules-04-00510],[@B44-biomolecules-04-00510]\], and there are a few reports describing the metal-binding ability of the middle- and C-terminal domains of hPrP \[[@B45-biomolecules-04-00510]\]. The interaction of full-length and truncated forms of PrP with Cu^2+^ has been investigated using a range of techniques including electron paramagnetic resonance \[[@B46-biomolecules-04-00510],[@B47-biomolecules-04-00510],[@B48-biomolecules-04-00510]\], circular dichroism (CD) \[[@B49-biomolecules-04-00510],[@B50-biomolecules-04-00510]\], X-ray crystallography \[[@B51-biomolecules-04-00510]\], nuclear magnetic resonance \[[@B52-biomolecules-04-00510],[@B53-biomolecules-04-00510]\], mass spectrometry (MS) \[[@B54-biomolecules-04-00510],[@B55-biomolecules-04-00510],[@B56-biomolecules-04-00510]\], Raman spectroscopy \[[@B57-biomolecules-04-00510],[@B58-biomolecules-04-00510]\], Fourier transform infrared spectroscopy \[[@B59-biomolecules-04-00510]\], and potentiometry \[[@B60-biomolecules-04-00510]\]. Although these methods have been useful, most can only detect metal binding that occurs during conformational conversion and cannot detect metal binding occurring without conformational change. Only MS is capable of detecting metal binding that does not occur in conjunction with conformational conversion. Electrospray ionization (ESI)-MS has the advantage of being able to directly provide speciation information, and has been used to analyze Cu^2+^ binding to hPrP octarepeat peptides \[[@B61-biomolecules-04-00510],[@B62-biomolecules-04-00510]\]. In addition, it is very interesting for us, NMR study carried out to determine the location and properties of metal-binding sites on the PrP \[[@B52-biomolecules-04-00510]\]. We reported the metal-binding abilities of synthetic fragment peptides covered from PrP60-230 to various divalent metal ions by a column switch (CS)-high-performance liquid chromatography (HPLC) system \[[@B63-biomolecules-04-00510],[@B64-biomolecules-04-00510]\]. The CS-HPLC can be detectable the metal-binding ability without conformational conversion, and also is very convenient method to avoid the contamination of metal ions which are serious obstacle for MS analysis. The metal-binding abilities of OP-repeat region to Cu^2+^, Ni^2+^ and Co^2+^ were very high with same degree, but Mn^2+^, Ca^2+^, Cd^2+^, Hg^2+^ and Al^3+^ did not bind. The Cu^2+^-binding abilities of the central region were higher than another ions such as Zn^2+^, Ni^2+^ and Co^2+^. The C-terminus region peptides showed the lower metal-binding ability comparison of the central region peptides. The data obtained using this method agreed well with previous CD analyses \[[@B38-biomolecules-04-00510]\] and NMR study \[[@B52-biomolecules-04-00510],[@B53-biomolecules-04-00510]\].

Our final goal of PrP study is not only to identify the critical part of PrP that contribute to acquire the enzyme resistance and aggregation but also to find inhibitor against neurotoxic diseases. We though that synthetic fragment peptides might be more useful and powerful toll than full-length PrP^C^. Thus, in this study, we focused on the MT-MMPs such as MT1-MMP and MT3-MMP that are expressed in the brain as PrP^C^-degrading protease and on Cu^2+^. The digestion of 21 prion fragment peptides by MT1-MMP, MT3-MMP, MMP-7, and human serum (HS) in the presence or absence of Cu^2+^ was analyzed by HPLC, and the cleavage sites were determined by LC-ESI-MS.

2. Results and Discussion
=========================

2.1. Preparation of Synthetic Fragment Peptides
-----------------------------------------------

The mature prion protein is composed of two structurally divergent parts, each of them making up roughly one half of the full-length prion protein: the less-structured N-terminal part with its flexible N-terminus and the compact and globular C-terminal domain ([Figure 1](#biomolecules-04-00510-f001){ref-type="fig"}).

We divided hPrP residues 60--230 into the following three domains in this study: hPrP60--91 as the octapeptide-repeat region (OP-repeat), hPrP92--168 as the central domain containing the neurotoxic domain and a hydrophobic core, and hPrP169--230 as the C-terminal domain containing a disulfate bridge (between amino acids 178 and 213) and two variably occupied N-glycosylation sites (amino acids 180 and 196). The amino-acid sequences of synthetic peptides were selected on the basis of the position of histidine (H) residues and the secondary structure of hPrP \[[@B11-biomolecules-04-00510]\]. Synthetic fragment peptides of various lengths covered hPrP residues 60--230. The synthetic ratio appeared to be very high, and the purity of the synthetic peptide was sufficient for use in this study. All peptides were characterized by ESI-MS using a direct-spray method.

The OP-repeat region, composed of four highly conserved, contiguous repeats of the eight-residue sequence PHGGGWGQ, is located in the flexible N-terminal region of hPrP. This domain also contains the copper-binding sites. Four peptides corresponding to one to four octarepeats, and the peptide PAGGGWGQ containing an H residue to a residue substitution, were synthesized. We also synthesized an additional eight fragment peptides corresponding to the middle domain of hPrP (amino acids 92--168), each of which contained one to four H residues. Five H-containing peptides and three non-H-containing peptides corresponding to the C-terminal domain of hPrP (amino acids 169--230) were synthesized and characterized in the same manner. The amino acid sequences of the synthetic peptides examined in this study, apart from the OP-region, are described in [Table 1](#biomolecules-04-00510-t001){ref-type="table"}.

2.2. Determination of Cleavage Sites
------------------------------------

Before carrying out this experiment, we tested the inhibitory activities of Cu^2+^ against MMPs, and confirmed that Cu^2+^ did not show any effects to MMPs in the concentration used here. To study the cleavage specificity of MT1-MMP, MT3-MMP, MMP-7, and HS, each purified peptide was incubated by purified recombinant MMPs (r-MMPs) independently, and products were analyzed by HPLC. As shown in [Figure 2](#biomolecules-04-00510-f002){ref-type="fig"}a, hPrP119-168, derived from the central region, was digested by MT1-MMP, and four peaks (Peak-1 to Peak-4) were observed. On the other hand, two peaks (Peak-5 and Peak-6) were observed on addition of Cu^2+^. This data indicates that proteolysis of hPrP119-168 by MT1-MMP is partially inhibited by Cu^2+^. In addition, remaining of peaks-5 and -6 proves that Cu^2+^ does not inhibit MT-1 MMP activity in this condition.

biomolecules-04-00510-t001_Table 1

###### 

Amino acid sequences of hPrP fragment peptides.

  Name            Sequence
  --------------- -------------------------------------------------------------------------------
  60--91(OP-4)    PHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQ
  60--83(OP-3)    PHGGGWGQPHGGGWGQPHGGGWGQ
  60--75(OP-2)    PHGGGWGQPHGGGWGQ
  60--67(OP--1)   PHGGGWGQ
  OP-1/HA         PAGGGWGQ
  92--168         GGGTHSQWNKPSKPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYYRENMHRYPNQVYYRPMDE
  119--168        GAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYYRENMHRYPNQVYYRPMDE
  134--168        MSRPIIHFGSDYEDRYYRENMHRYPNQVYYRPMDE
  148--168        RYYRENMHRYPNQVYYRPMDE
  92--106         GGGTHSQWNKPSKPK
  107--119        TNMKHMAGAAAAG
  132--144        SAMSRPIIHFGSD
  150--159        YRENMHRYPN
  169--192        YSNQNNFVHDCVNITIKQHTVTTT
  169--179        YSNQNNFVHDC
  169--178        YSNQNNFVHD
  175--189        FVHDCVNITIKQHTV
  180--192        VNITIKQHTVTTT
  180--192/HA     VNITIKQATVTTT
  193--230        TKGENFTETDVKMMERVVEQMCITQYERESQAYYQRGS
  215--230        ITQYERESQAYYQRGS

To determine the cleavage site, the peaks (Peak-1 to -6) illustrated in [Figure 2](#biomolecules-04-00510-f002){ref-type="fig"} were collected and analyzed by ESI-MS with direct injection. Peaks-1 and -2 were identified as hPrP161--168 and hPrP138--160, respectively. Peaks-3 and -5 were identified as hPrP138--168. Peak-4 and -6 were identified as a mixture of hPrP119--137 and hPrP119--168. Thus, we conclude that MT1-MMP digests PrP fragment peptide, the Cu^2+^-binding peptides acquires the MT1-MMP resistance.

To identify partner fragments with identified peaks described in [Figure 2](#biomolecules-04-00510-f002){ref-type="fig"}, the reaction mixtures were analyzed by LC-ESI-MS. Three major peaks were detected on the total ion chromatogram ([Figure 3](#biomolecules-04-00510-f003){ref-type="fig"}a; XIC), which were identified as hPrP119--127, hPrP128--137, and hPrP119--137 on the extracted ion chromatograms ([Figure 3](#biomolecules-04-00510-f003){ref-type="fig"}b--d). In addition, hPrP161--168, hPrP138--160, and hPrP138--168 were also identified as fragment peptide that. On the basis of LC-MS analysis, three cleavage sites, ^127^Gly-Tyr^128^, ^137^Pro-Ile^138^ and ^16^Gln-Val^161^ were additionally identified ([Figure 3](#biomolecules-04-00510-f003){ref-type="fig"}e--g). The cleavage sites of each peptide by MT1-MMP, MT3-MMP, MMP-7, and HS were determined in the same manner ([Figure 4](#biomolecules-04-00510-f004){ref-type="fig"} and [Figure 5](#biomolecules-04-00510-f005){ref-type="fig"}). These data ([Figure 2](#biomolecules-04-00510-f002){ref-type="fig"} and [Figure 3](#biomolecules-04-00510-f003){ref-type="fig"}) suggests interesting events that.

![Determination of the cleavage sites on hPrP119--168 by MT1-MMP, and inhibitory effects of Cu^2+^. Reversed-phase HPLC revealed four peaks (Peaks-1 to -4) and two peaks (Peaks-5 and -6), respectively, from reaction mixtures in the absence (**a**) and presence (**b**) of Cu^2+^. Sequence analysis of each peak was performed by direct-injection ESI-MS.](biomolecules-04-00510-g002){#biomolecules-04-00510-f002}

![Sequence analysis by LC-ESI-QTOF MS of fragment peptides in the reaction mixture of hPrP119--168 in the absence of Cu^2+^. (**a**) Total ion chromatogram (TIC) of reaction mixture. Extracted ion chromatogram monitored by hPrP119--127 fragment ion (**b**), by hPrP128--137 fragment ion (**c**), by hPrP119--137 fragment ion (**d**), by hPrP161--168 fragment ion (**e**), by hPrP138-160 fragment ion (**f**), by hPrP138-168 fragment ion (**g**).](biomolecules-04-00510-g003){#biomolecules-04-00510-f003}

![Cleavage sites on the central region peptides. The cleavage sites are marked with colored triangles: MT1-MMP, red arrow; MT3-MMP, yellow arrow; MMP-7, green arrow; HS, pink arrow and the inhibited sites (blue) are indicated.](biomolecules-04-00510-g004){#biomolecules-04-00510-f004}

![Cleavage sites on the C-terminus region peptides. The cleavage sites are marked with colored triangles: MT1-MMP, red arrow; MT3-MMP, yellow arrow; MMP-7, green arrow; HS, pink arrow and the inhibited sites (blue) are indicated.](biomolecules-04-00510-g005){#biomolecules-04-00510-f005}

HPrP119--168 may contain the important amino acid sequence for aggregation of PrP. In comparison with peak heights of each peak in [Figure 2](#biomolecules-04-00510-f002){ref-type="fig"}, peak-5 is lower than peak-3, it suggests hPrP119--168 acquires the enzyme resistance by binding to Cu^2+^. We think that this event may occur with conformational change with Cu^2+^-binding. In addition, although peak-6 contains hPrP119--168 and hPrP119--137, peak heights of peak-6 is very low. These phenomena suggest that hPrP119--168 may aggregate by Cu^2+^-binding. However, unfortunately, the Cu^2+^-binding peptide was not identified in the acidic conditions used in this LC-MS analysis.

In the case of the OP-repeat region, no peptide was digested by the MMPs tested here. The cleavage sites in the central and C-terminal regions are described in [Figure 4](#biomolecules-04-00510-f004){ref-type="fig"} and [Figure 5](#biomolecules-04-00510-f005){ref-type="fig"}, respectively. In the central region, many cleavage sites were identified. hPrP92--168, the longest fragment peptide in the central region, was digested with MMPs and HS. Four, five and seven cleavage sites were identified by MT1-MMP, MT3-MMP, and MMP-7, respectively: these digestions were inhibited in the presence of Cu^2+^. Three cleavage sites were identified with HS. Interestingly, the cleavage sites of hPrP119--168 and hPrP134--168 were almost the same as those of hPrP92--168, but the inhibitory effect of Cu^2+^ on MMP-7 activity was completely different with hPrP119--168 and hPrP134--168 from that with hPrP92--168. hPrP148--168 was digested with MT1-MMP and MT3-MMP, but not with MMP-7 and HS. hPrP150--159 was digested with MMP-7 and HS, but not with MT3-MMP. hPrP132--144 was digested with HS, despite there being no HS cleavage site in hPrP92-168. In the case of hPrP107--119, only one cleavage site, by MT3-MMP, was identified: the cleavage sites found with MMP-7 and HS in hPrP92--168 were not present. The N-terminus fragment peptide of hPrP92--168, hPrP92--106, was not digested with MMPs or HS. In comparison with all data described in [Figure 4](#biomolecules-04-00510-f004){ref-type="fig"}, the cleavage sites by MT1-MMP or MT3-MMP, and those inhibitory effects with Cu^2+^ were very similar, although the cleavage sites by MMP-7 were different from MT1-MMP or MT3-MMP. In addition, the inhibitory pattern with Cu^2+^ of hPrP92--168 is completely different from that of hPrP119--168 and hPrP134--168. These differences may be occurred from the conformation of Cu^2+^-binding fragment peptide.

In the case of the C-terminus region, this region forms β-sheet structure in nature PrP^C^ \[[@B11-biomolecules-04-00510]\], there were a few cleavage sites. hPrP193--230 was cleaved by MT1-MMP and MMP-7 between ^224^Ala--^225^Tyr and ^214^Cys--^215^Ile, respectively. Cleavage by MMP-7 but not MT1-MMP was inhibited in the presence of Cu^2+^. Interestingly, hPrP215-230, the C-terminal end of hPrP193--230, was cleaved by MT1-MMP, but this cleavage reaction was inhibited in the presence of Cu^2+^. In addition, this peptide was cleaved by MT3-MMP, which was not inhibited in the presence of Cu^2+^. CS-HPLC analysis showed that this fragment peptide binds to Cu^2+^ \[[@B64-biomolecules-04-00510]\]. CD analysis indicated that the C-terminus fragment peptide takes a β-sheet structure on treatment with Cu^2+^ or in acidic conditions (data not shown). These differences in cleavage pattern and Cu^2+^ inhibitory effects between hPrP215--230 and hPrP193--230 might be attributed to the conformational differences. hPrP169--192 was not digested with any MMPs or HS, but the shorter fragment peptides, hPrP169--192, hPrP169--179, hPrP175--189, and hPrP180--192, were digested with MMPs. Interestingly, HS did not digest the C-terminal region. In addition, only MT1-MMP digested hPrP193--230 between ^224^Ala--^225^Tyr, at the C-terminal end of hPrP. Other fragment peptides were not digested with MMPs or HS. This study reveals that MMPs digest PrP fragment peptides at many sites, inhibitory effects with Cu^2+^ is related to the conformational change of Cu^2+^-binding peptide but not result in the direct inhibition to MMPs with Cu^2+^.

PrP^C^ is subject to diverse proteolytic processing, including a-cleavage within the neurotoxic domain (hPrP105--125 in mice), b-cleavage around amino acid position 90, and shedding near the plasma membrane to release almost full-length PrP^C^ into the extracellular space. ADAMs are thought to be candidate proteinases for PrP^C^ degradation \[[@B65-biomolecules-04-00510]\]. The domain structure of MMPs is similar to that of ADAMs, and both enzymes are Zn^2+^-dependent metalloproteinases ([Figure 6](#biomolecules-04-00510-f006){ref-type="fig"}). This study suggests that MMPs, especially MT-MMPs, may act in the physiological processing of PrP^C^.

![Domain structures of MT-MMPs (**a**) and ADAMs (**b**).](biomolecules-04-00510-g006){#biomolecules-04-00510-f006}

Recntly, roles of matrix metalloproteinases and their targets in epileptogenesis and seizures were reviewed by Mizoguchi and Yamada \[[@B66-biomolecules-04-00510]\]. We here discuss the role of MT-MMPs for PrP homeostasis in cell. Up to date, it is generally accepted that Prion disease occurs in young generation and is caused by the conformational change from PrP^C^ to PrP^Sc^. This conformational change is related to Cu^2+^-binding. The amino acid mutation in PrP^Sc^ is mainly occurred in C-terminus end (C-terminal region in this study) and the central region in next. The fragment peptides in the C-terminus region showed the enzyme resistance and take β-sheet structure with Cu^2+^-binding or in lower pH (data not shown). Thus, we think that the enzyme resistance and aggregation of PrP^Sc^ is caused by conformational change in the C-terminus region. In the case of amino acid mutation, insertion or deletion on OP-repeat region, the homeostasis of Cu^2+^ is in out of order that may promote Cu^2+^-binding to the central and the C-terminus regions. In any case, we think the most important event is the conformational change on the C-terminus region. The data obtained from Prion fragment peptides here support the results reported by many researchers \[[@B67-biomolecules-04-00510],[@B68-biomolecules-04-00510],[@B69-biomolecules-04-00510]\]. We know we are opening ourselves to criticism, but we would like to present here a bold and challenging hypothesis that could be applicable to explain the another neurotoxic diseases, such as Alzheimer's and Parkinson's diseases. With increasing age, the concentration of Cu^2+^ in the brain increases by disorder of metabolism \[[@B70-biomolecules-04-00510],[@B71-biomolecules-04-00510],[@B72-biomolecules-04-00510]\], and Zn^2+^ concentration decreases \[[@B73-biomolecules-04-00510]\]. Once the amount of Cu^2+^ exceeds the control range of the OP-repeat region, which controls Cu^2+^ homeostasis, sites in PrP^C^ can capture the excess Cu^2+^ and acquire resistance against cellular proteinase with a structural change from α-helix to β-sheet. In addition, the proteolytic activity of MMPs is weakened by the low concentration of Zn^2+^. As a result, the full-length PrP^C^ could be taken into the cell via endocytosis and the structure could change to PrP^Sc^, allowing PrP to aggregate in the cell ([Figure 7](#biomolecules-04-00510-f007){ref-type="fig"}).

![Our hypothesis of the role of membrane-type matrix metalloproteinase and Cu^2+^ for the regulation of PrP^C^. First step (**1**) binding to Cu^2+^; Second step (**2**) conformational change and acquiring proteolytic resistance; Third step (**3**) endocytosis; Fourth step (**4**) conformational change to PrP^Sc^ by lower pH in cell; Final step (**5**) aggregation of PrP^Sc^ and cell death.](biomolecules-04-00510-g007){#biomolecules-04-00510-f007}

3. Experimental
===============

3.1. Preparation of Recombinant Human MMPs
------------------------------------------

Recombinant human MT1-MMP, MT3-MMP and MMP-7 (matrilysin) were prepared as described previously \[[@B19-biomolecules-04-00510],[@B74-biomolecules-04-00510]\]. In brief, the cDNAs for procatalytic domains of human MT1-MMP, MT3-MMP and MMP-7 were prepared by polymerase chain reactions using sets of primers (5\' primer, GGCGGATCCATGCTCGCCTCCCTCGGCTCG, 3\' primer, GCCGTCGACGTTCCCGTCACAGATGTTGGG; 5\' primer GGCGGATCCATGATTTTATGTGCTACAGTCTGC, 3\' primer GCCGTCGACCCCATCACAGATGTTGGGTTTGGC; and 5\' primer, GGCGGATCCATGCTGCCGCTGCCTCAGGAG, 3\' primer, GCCGTCGACTTTCTTTCTTGAATTACTTCT; respectively) based on the reported sequences, and the templates (pSG-GelA having a 3.3 Kb cDNA fragment of MMP-2, poly(A)+ RNA isolated from a human rectal carcinoma cell line \[CaR-1\], and pME18S-MT-MMPs having a 3.5 Kb cDNA fragment of MT1-MMP, respectively). The resulting PCR fragments were inserted into the bacterial expression plasmid pTH-72, having a tandem repeat of the T7 promoter and a hexahistidine-Tag-encoding sequence. The expression, purification, and refolding of the human recombinant MMPs were performed as follows: human recombinant proMMPs were produced in *E. coli* strain BL21 (DE3) transfected with the corresponding expression plasmids derived from pTH-72, solubilized in 8 M urea/10 mM Tris-HCl (pH 8.0)/100 mM Na-phosphate/100 mM β-mercaptoethanol, purified with Ni-NTA resin (QIAGEN Inc., Valencia, CA, USA), and refolded by reducing the urea concentration.

3.2. Materials
--------------

Trifluoroacetic acid (TFA) (Peptide Synthesis Grade), diethyl ether, acetonitrile (CH~3~CN, HPLC grade), 2-amino*-*2-hydroxymethyl-1,3-propanediol (Tris), HgCl~2~, ZnCl~2~, MnCl~2~·4H~2~O, CaCl~2~·2H~2~O, and CoCl~2~·6H~2~O were purchased from Wako Pure Chemical Industries, Ltd., Inc. (Osaka, Japan). Thioanisole, CuCl~2~·2H~2~O, CdCl~2~·2 1/2H~2~O, and NiCl~2~·6H~2~O were obtained from Nacalai Tesque (Kyoto, Japan). 1,2-ethanedithiol and AlCl~3~·6H~2~O were obtained from Kanto Chemical Co., Inc. (Osaka, Japan). Ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA-2Na) and HCl were purchased from Kishida Chemical Co., Ltd. (Osaka, Japan). Piperidine was obtained from Sigma-Aldrich Japan (Tokyo, Japan). *O*-(7-Azabenzo-triazol-1-yl)-*N*,*N*,*N*′,*N*′-tetra-methyluronium hexafluorophosphate (HATU), *N*,*N*-dimethylformamide, 2.0 M *N*,*N*-diisopropylethylamine/*N*-methylpyrrolidone (DIEA), dichloromethane, and *N*-methylpyrrolidone, fluorenylmethoxycarbonyl (Fmoc)-[l]{.smallcaps}-amino acid preloaded resin were purchased from Applied Biosystems (ABI, div. Perkin Elmer, Bedford, MA, USA). Fmoc-[l]{.smallcaps}-amino acid was obtained from ABI, AAPPTec, LLC (Louisville, KY, USA) and Peptide Institute, Inc. (Osaka, Japan). Milli-Q water was used for all experiments.

3.3. Preparation of Synthetic Fragment Peptide
----------------------------------------------

Fragment peptides corresponding to amino acid sequences from human prion protein were synthesized using an automated ABI model 433A peptide synthesizer (0.1 mmoL scale with preloaded resin) from Fmoc-protected [l]{.smallcaps}-amino acid derivatives purchased from ABI \[[@B63-biomolecules-04-00510]\]. After deprotection according to the manufacturer's protocol, each peptide was purified using reversed-phase HPLC (Capcell Pak C18 column, SG, 10 or 15 mm i.d. × 250 mm; Shiseido Co., Ltd., Tokyo, Japan) with a linear gradient elution from 0.1% TFA to 50% or 70% CH~3~CN containing 0.1% TFA over 30 min. The primary peak was collected and then lyophilized. Peptide purity was confirmed using an analytical HPLC system as described below. Each purified peptide was characterized by ESI-MS using a Qstar Elite Hybrid LC/MS/MS system (ABI, Framingham, MA, USA).

3.4. Analytical HPLC
--------------------

Cleavage reactions and the purity of synthetic peptides were confirmed by analytical reversed-phase HPLC (Cosmosil 5C~18~-AR-II column, 5 mm, 4.6 mm i.d. × 150 mm; Nacalai Tesque, (Kyoto, Japan) with a flow rate of 1.0 mL/min and a linear gradient elution from 0.1% TFA to 70% CH~3~CN containing 0.1% TFA over 15 min. The column eluate was monitored with a photodiode-array detector (SPD-M20A; Shimadzu, Kyoto, Japan).

3.5. Determination of Cleavage Sites
------------------------------------

Each purified protein fragment peptide (final conc. 0.1 mM) was individually incubated with recombinant MT1-MMP or MT3-MMP in the presence or absence of Cu^2+^ (two equivalent molecule of His residue in each peptide; final conc. 0 to 0.8 mM) at 37 °C for 1 day in assay buffer (final conc. 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10 mM CaCl~2~, 5 mM ZnCl~2~, 0.005% Briji 35, 3 mM NaN~3~). After boiling for 5 min, the reaction mixtures were analyzed by analytical HPLC monitored with a photodiode-array UV detector. The determination of cleavage sites was performed by ESI-MS and LC-ESI-MS analysis using a Qstar Elite Hybrid LC/MS/MS system (ABI). Recombinant MMP-7 and HS were also tested as control.

4. Conclusions
==============

In this study, we found that MT1-MMP and MT3-MMP degrade hPrP fragment peptides with many cleavage sites, and that these activities were inhibited by treatment with Cu^2+^. hPrP61--90 from the OP-repeat region was cleaved by HS, but showed protease resistance against MMPs. On the other hand, hPrP92--168 from the central region was cleaved by MT1-MMP, MT3-MMP and MMP-7. These cleavage reactions were inhibited by treatment with Cu^2+^. The C-terminal peptides possessed higher resistance than the central region. hPrP193--230, the longest fragment peptide of the C-terminus, was cleaved by MT1-MMP and MMP-7. Interestingly, cleavage by MT1-MMP was not inhibited by treatment with Cu^2+^, unlike cleavage by MMP-7. These data indicate the possibility that MT1-MMP might shed hPrP in a similar way to ADAMs. Although we are now on the half way to our final goal, the data obtained from this study may be useful to open the next door of PrP research.
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